Skip to Main Content

Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

Conditions

Immune System

Phase II

What is the purpose of this trial?

The purpose of the study is to evaluate safe and efficacious doses of AMG 570 for the treatment of active systemic lupus erythematosus (SLE) in patients who are not responding to the current standard of care. AMG 570 is a bispecific peptide immunoglobulin (Ig) G2 antibody conjugate. This study will help determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects have ongoing disease activity despite treatment with standard of care therapies. If you meet the study requirements and are enrolled, you will be in this study for about 52 weeks.

  • Trial with
    Amgen, Inc.
  • Start Date
    04/27/2021
  • End Date
    05/19/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/22/2021
  • Study HIC
    #2000027251